Clinical Trials Logo

Coronary Disease clinical trials

View clinical trials related to Coronary Disease.

Filter by:

NCT ID: NCT03316833 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Rolex Registry

Rolex
Start date: November 1, 2017
Phase: N/A
Study type: Observational

The primary objective of this study is to assess the safety and efficacy of the new-generation zotarolimus-eluting stent Resolute Onyx in the treatment of unprotected left main coronary artery disease (ULMCAD), both isolated or in association with two- or three-vessel coronary artery disease.

NCT ID: NCT03315234 Recruiting - Clinical trials for Coronary Artery Disease

Correlation of Genetic Polymorphisms and Clinical Parameters With the Complexity of Coronary Artery Disease

Start date: September 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the research project is to investigate the potential association of 6 genetic polymorphisms with the complexity and the severity of coronary artery disease (SYNTAX score). The aim of the study is to combine genetic, clinical and laboratory data in order to create a prognostic tool that will enable an individualized therapeutic patient approach.

NCT ID: NCT03313752 Recruiting - Clinical trials for Type2 Diabetes Mellitus

Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity

DapaHeart
Start date: December 1, 2017
Phase: Phase 3
Study type: Interventional

A Phase III, single-centre, randomized, 2-arm, parallel-group, double blind, placebo-controlled study, consisting of a screening phase (Days -14 to -1), a 4-week double-blind, placebo-controlled treatment phase and a 4-week follow-up phase. Subjects: Type 2 diabetic patients with coronary artery disease (CAD) not requiring revascularization, with sub-optimal glycemic control (HbA1c 7.5-8.5%) on their current anti-hyperglycemic regimen Subjects will be randomized in a 1:1 ratio to dapagliflozin or placebo. Subjects will undergo screening assessment in the 14-day period preceding administration of the first dose of study drug on Day 1. Primary Objective The primary objective is to assess the effect of dapagliflozin on myocardial insulin sensitivity Secondary Objective The secondary objective is to assess global heart function, and metabolic systemic effects of dapagliflozin, and glycemic control. The study aims to enroll patients with type 2 diabetes with poor glycemic control, and with coronary artery disease not requiring revascularization, who have already undergone, under routine cardiological assessment, a positron emission tomography (PET) 13NH3 scan in order to assess the cardiovascular function. Thus, the study aims to assess whether the improvement in cardiac metabolism obtained with dapagliflozin is greater than that obtained with normal clinical practice (according to Standards of Care).

NCT ID: NCT03312855 Not yet recruiting - Clinical trials for Stable Coronary Artery Disease

A Phase II Randomised Double-blind, Placebo-controlled Study of Revacept in Patients With Stable Coronary Artery Disease

Start date: November 2017
Phase: Phase 2
Study type: Interventional

The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.

NCT ID: NCT03312179 Completed - Clinical trials for Coronary Artery Disease

STEMI and Incretins Treatment

Start date: January 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis, represent a clinical relevant problem. The management and prognosis of these patents are supported by few literature data. Therefore, in this study authors enrolled real world diabetic vs. non diabetic patients admitted for STEMI and associated to multi vessels coronary disease. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. In these patients authors studied all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up.

NCT ID: NCT03310801 Completed - Clinical trials for Coronary Artery Disease

LAAO With DAPT Versus Antithrombotic Therapy

Start date: August 1, 2016
Phase: N/A
Study type: Observational

This study will retrospectively review and compare clinical outcomes between left atrial appendage occlusion with dual antiplatelet therapy versus conventional antithrombotic therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation.

NCT ID: NCT03308539 Recruiting - Clinical trials for Myocardial Infarction

Prediction of Coronary Artery Disease Severity by Epicardial Adipose Tissue Thickness

Start date: November 1, 2017
Phase: N/A
Study type: Observational

is to test the hypotheses that epicardial adipose tissue can be a marker of severity of coronary artery disease in myocardial infarction patients

NCT ID: NCT03307213 Not yet recruiting - Clinical trials for Coronary Artery Disease

BioFreedom QCA Study in CAD Patients

BioFreedomQCA
Start date: January 1, 2018
Phase: N/A
Study type: Interventional

This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.

NCT ID: NCT03305926 Not yet recruiting - Clinical trials for Coronary Artery Disease

Connected Rehabilitation: an Alternative to Conventional Cardiovascular Rehabilitation?

eRCV
Start date: December 2017
Phase: N/A
Study type: Interventional

Cardiovascular rehabilitation (CVR) has major beneficial effects by improving physical capacity, accelerating return to activities and reinsertion and reducing mortality. It associates reconditioning to effort and therapeutic education for the optimal control of " risk factors ". It corresponds to a global approach to patients, thus counterbalancing the tendency to hyperspecialise in medicine. However, because of the lack of specialised centres, only a small proportion of patients (≈30%) are able to benefit. Numerical tools used in e-health, the deployment of the Internet and certain " connected " devices may provide alternatives outside hospital, by enabling the follow-up of patients and their physiological parameters (heart rate, blood pressure, weigh, physical activity…), and the adaptation - using an interactive web platform - of the physical activity programme, nutrition, compliance with medication and weaning from smoking. This project proposes to evaluate the effects of a so-called " connected " CVR programme, and to show its non-inferiority compared with a conventional CVR.

NCT ID: NCT03304496 Recruiting - Clinical trials for Coronary Artery Disease

Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.

NITRAD-Sub
Start date: March 30, 2017
Phase: Phase 4
Study type: Interventional

Femoral artery approach to perform coronary procedures is considered the standard technique for vascular access due to optimal catheter control, lower thromboembolic complications and immediate access due to the large diameter of the artery. Trans-radial approach has been shown to reduce major bleeding complications, vascular complications related to the site of puncture, including death from all causes, and to prevent post-procedure limb rest, greater comfort for patients, immediate ambulation, early discharge and reduction of costs. Previous studies have shown that intravenous, topical and intraarterial use of nitroglycerin produces vasodilation of the radial artery. Extravascular (subcutaneous) administration of nitroglycerin is extremely effective in restoring the radial pulse, and allows adequate cannulation.